

, Jae-Seung Yun2*
, Bongseong Kim3, Hun-Sung Kim1,4, Jae-Hyoung Cho1,4, Yong-Moon Mark Park5,6, Kyungdo Han3

1Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea
4Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea
5Department of Epidemiology, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA
6Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea E-mail: hwanx2@catholic.ac.kr
Department of Statistics and Actuarial Science, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul 06978, Korea E-mail: hkd917@naver.com Copyright © 2025 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
PubReader
ePub Link
Cite this Article
| Characteristic | Total | IDLA (–) | IDLA (+) |
|---|---|---|---|
| Number | 2,432,613 | 2,177,477 | 255,136 |
| Age, yr | 59.7±12.0 | 60.0±12.0 | 57.1±11.9 |
| Male sex | 1,477,117 (60.7) | 1,320,781 (60.7) | 156,336 (61.3) |
| Smoking | |||
| Non | 1,332,065 (54.7) | 1,201,581 (55.2) | 130,484 (51.1) |
| Ex | 551,677 (22.7) | 502,419 (23.1) | 49,258 (19.3) |
| Current | 548,871 (22.6) | 473,477 (21.7) | 75,394 (29.6) |
| Drinking | |||
| Non | 1,399,724 (57.5) | 1,258,215 (57.8) | 141,509 (55.5) |
| Mild | 810,413 (33.3) | 722,655 (33.2) | 87,758 (34.4) |
| Heavy | 222,476 (9.2) | 196,607 (9.0) | 25,869 (10.1) |
| Regular exercise | 529,781 (21.8) | 479,126 (22.0) | 50,655 (19.9) |
| Low income | 514,787 (21.2) | 400,881 (18.4) | 113,906 (44.7) |
| Hypertension | 1,412,106 (58.1) | 1,269,592 (58.3) | 142,514 (55.9) |
| Dyslipidemia | 1,391,280 (57.2) | 1,249,187 (57.4) | 142,093 (55.7) |
| CKD | 194,858 (8.0) | 177,372 (8.2) | 17,486 (6.9) |
| Height, cm | 162.8±9.4 | 162.8±9.4 | 163.1±9.2 |
| Weight, kg | 67.5±12.6 | 67.4±12.5 | 67.8±13.1 |
| BMI, kg/m2 | 25.3±3.5 | 25.3±3.5 | 25.4±3.8 |
| Waist circumference, cm | 86.2±9.0 | 86.2±8.9 | 86.1±9.5 |
| Systolic BP, mm Hg | 128.5±15.0 | 128.5±15.0 | 128.1±15.3 |
| Diastolic BP, mm Hg | 78.1±9.9 | 78.0±9.9 | 78.5±10.2 |
| Fasting glucose, mg/dL | 144.5±45.6 | 144.1±45.0 | 147.9±49.8 |
| Total cholesterol, mg/dL | 185.1±43.6 | 184.8±43.5 | 188.3±44.8 |
| HDL-cholesterol, mg/dL | 50.9±14.7 | 50.9±14.6 | 51.2±15.4 |
| LDL-cholesterol, mg/dL | 103.0±38.4 | 102.9±38.3 | 104.5±39.2 |
| Triglyceride, mg/dL | 134 (93–197) | 134 (93–196) | 140 (96–208) |
| eGFR, mL/min/1.73 m2 | 88.2±19.1 | 88.0±19.1 | 90.1±19.3 |
| Insulin treatment | 237,716 (9.8) | 212,400 (9.8) | 25,316 (9.9) |
| Oral antidiabetic medication ≥3 | 656,275 (27.0) | 589,113 (27.1) | 67,162 (26.3) |
| Duration of diabetes, yr | 5.3±5.1 | 5.4±5.1 | 4.7±4.9 |
| Variable | Number | No. of events | IR, /1,000 PY | HR (95% CI) |
|||
|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | ||||
| IDLA (–) | 2,177,477 | 23,707 | 1.90 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| IDLA (+) | 255,136 | 2,984 | 2.04 | 1.08 (1.04–1.11) | 1.21 (1.17–1.26) | 1.07 (1.03–1.11) | 1.10 (1.06–1.14) |
| Income | IDLA | Number | No. of event | Incidence rate, /1,000 PY | HR (95% CI) |
|
|---|---|---|---|---|---|---|
| Risk trends | Effect modification | |||||
| Medical aid | No | 28,360 | 588 | 3.70 | 1.50 (1.38–1.64) | 1 (Ref) |
| Yes | 24,662 | 561 | 4.13 | 1.44 (1.32–1.57) | 0.96 (0.85–1.08) | |
| Q1 | No | 372,521 | 4,215 | 1.96 | 1.10 (1.06–1.14) | 1 (Ref) |
| Yes | 89,244 | 1,110 | 2.18 | 1.22 (1.15–1.30) | 1.11 (1.04–1.19) | |
| Q2 | No | 398,511 | 4,295 | 1.87 | 1.12 (1.08–1.17) | 1 (Ref) |
| Yes | 63,471 | 662 | 1.81 | 1.22 (1.13–1.32) | 1.09 (1.00–1.18) | |
| Q3 | No | 559,452 | 5,874 | 1.83 | 1.05 (1.02–1.09) | 1 (Ref) |
| Yes | 47,911 | 394 | 1.42 | 1.09 (0.98–1.21) | 1.04 (0.94–1.15) | |
| Q4 | No | 818,633 | 8,735 | 1.86 | 1 (Ref) | 1 (Ref) |
| Yes | 29,848 | 257 | 1.49 | 0.99 (0.88–1.12) | 0.99 (0.88–1.12) | |
| Subgroup | IDLA | Number | No. of event | IR, /1,000 PY | HR (95% CI) | P for interaction |
|---|---|---|---|---|---|---|
| Male | No | 1,320,781 | 15,763 | 2.09 | 1 (Ref) | 0.324 |
| Yes | 156,336 | 2,073 | 2.33 | 1.12 (1.07–1.17) | ||
| Female | No | 856,696 | 7,944 | 1.60 | 1 (Ref) | |
| Yes | 98,800 | 911 | 1.59 | 1.07 (1.00–1.15) | ||
| Age <65 yr | No | 1,397,390 | 10,761 | 1.32 | 1 (Ref) | 0.002 |
| Yes | 190,240 | 1,932 | 1.76 | 1.16 (1.11–1.22) | ||
| Age ≥65 yr | No | 780,087 | 12,946 | 2.99 | 1 (Ref) | |
| Yes | 64,896 | 1,052 | 2.90 | 1.03 (0.96–1.09) | ||
| Current smoking (–) | No | 1,704,000 | 18,946 | 1.93 | 1 (Ref) | 0.307 |
| Yes | 179,742 | 2,052 | 1.98 | 1.09 (1.04–1.14) | ||
| Current smoking (+) | No | 473,477 | 4,761 | 1.76 | 1 (Ref) | |
| Yes | 75,394 | 932 | 2.18 | 1.14 (1.06–1.22) | ||
| Alcohol consumption (–) | No | 1,258,215 | 16,916 | 2.36 | 1 (Ref) | <0.001 |
| Yes | 141,509 | 2,011 | 2.49 | 1.05 (1.00–1.10) | ||
| Alcohol consumption (+) | No | 919,262 | 6,791 | 1.27 | 1 (Ref) | |
| Yes | 113,627 | 973 | 1.49 | 1.22 (1.14–1.31) | ||
| Regular exercise (–) | No | 1,698,351 | 19,174 | 1.97 | 1 (Ref) | 0.839 |
| Yes | 204,481 | 2,446 | 2.09 | 1.11 (1.06–1.15) | ||
| Regular exercise (+) | No | 479,126 | 4,533 | 1.63 | 1 (Ref) | |
| Yes | 50,655 | 538 | 1.84 | 1.09 (1–1.20) | ||
| Obesity (–) | No | 1,064,991 | 12,510 | 2.06 | 1 (Ref) | 0.001 |
| Yes | 123,931 | 1,642 | 2.33 | 1.17 (1.11–1.24) | ||
| Obesity (+) | No | 1,112,486 | 11,197 | 1.74 | 1 (Ref) | |
| Yes | 131,205 | 1,342 | 1.77 | 1.03 (0.97–1.09) | ||
| CKD stage 1 (eGFR ≥90 mL/min/1.73 m2) | No | 1,105,432 | 2,903 | 0.45 | 1 (Ref) | <0.001 |
| Yes | 139,349 | 474 | 0.59 | 1.30 (1.18–1.43) | ||
| CKD stage 2 (60≤ eGFR <90 mL/min/1.73 m2) | No | 894,673 | 5,617 | 1.09 | 1 (Ref) | |
| Yes | 98,301 | 795 | 1.41 | 1.22 (1.13–1.32) | ||
| CKD stage 3 (30≤ eGFR <60 mL/min/1.73 m2) | No | 167,261 | 10,377 | 11.7 | 1 (Ref) | |
| Yes | 16,449 | 1,189 | 13.6 | 1.06 (0.99–1.12) | ||
| CKD stage 4–5 (eGFR <30 mL/min/1.73 m2) | No | 10,111 | 4,810 | 139.3 | 1 (Ref) | |
| Yes | 1,037 | 526 | 149.8 | 0.94 (0.86–1.03) | ||
| Insulin treatment (–) | No | 1,965,077 | 13,981 | 1.23 | 1 (Ref) | 0.134 |
| Yes | 229,820 | 1,772 | 1.34 | 1.13 (1.07–1.19) | ||
| Insulin treatment (+) | No | 212,400 | 9,726 | 8.56 | 1 (Ref) | |
| Yes | 25,316 | 1,212 | 8.95 | 1.07 (1.00–1.13) | ||
| OAM ≤2 | No | 1,588,364 | 14,543 | 1.59 | 1 (Ref) | 0.187 |
| Yes | 187,974 | 1,795 | 1.66 | 1.08 (1.03–1.14) | ||
| OAM ≥3 | No | 589,113 | 9,164 | 2.73 | 1 (Ref) | |
| Yes | 67,162 | 1,189 | 3.11 | 1.14 (1.07–1.21) | ||
| DM duration <5 yr | No | 1,162,352 | 3,927 | 0.58 | 1 (Ref) | 0.262 |
| Yes | 149,400 | 602 | 0.70 | 1.13 (1.04–1.24) | ||
| DM duration 5–10 yr | No | 455,896 | 4,225 | 1.61 | 1 (Ref) | |
| Yes | 53,042 | 702 | 2.30 | 1.15 (1.06–1.25) | ||
| DM duration ≥10 yr | No | 559,229 | 15,555 | 4.97 | 1 (Ref) | |
| Yes | 52,694 | 1,680 | 5.71 | 1.07 (1.02–1.13) |
Values are presented as mean±standard deviation, number (%), or median (interquartile range). IDLA, individuals with diabetes living alone; CKD, chronic kidney disease; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate.
Model 1: unadjusted; Model 2: adjusted for age and sex; Model 3: adjusted for model 2+smoking, drinking, regular exercise, income, body mass index, hypertension, dyslipidemia, and estimated glomerular filtration rate; Model 4: adjusted for model 3+duration of diabetes, insulin treatment, and oral antidiabetic medications. IR, incidence rate; PY, person-year; HR, hazard ratio; CI, confidence interval; IDLA, individuals with diabetes living alone.
Adjusted for age, sex, smoking, drinking, regular exercise, income, body mass index, hypertension, dyslipidemia, estimated glomerular filtration rate, duration of diabetes, insulin treatment, and oral antidiabetic medications. IDLA, individuals with diabetes living alone; PY, person-year; HR, hazard ratio; CI, confidence interval; Q, quartile.
Adjusted for age, sex, smoking, drinking, regular exercise, income, body mass index, hypertension, dyslipidemia, estimated glomerular filtration rate, duration of diabetes, insulin treatment, and oral antidiabetic medications. IDLA, individuals with diabetes living alone; IR, incidence rate; PY, person-year; HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; OAM, oral antidiabetic medication; DM, diabetes mellitus.
